BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 16:16:34 By Nasdaq GlobeNewswire

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

09 Jan 2024 11:02:26 By Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

08 Jan 2024 09:00:26 By Nasdaq GlobeNewswire

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting

11 Dec 2023 09:25:04 By Nasdaq GlobeNewswire

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

09 Dec 2023 17:30:16 By Nasdaq GlobeNewswire

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

08 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

07 Dec 2023 09:15:10 By Nasdaq GlobeNewswire

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

05 Dec 2023 08:30:23 By Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

27 Nov 2023 08:30:27 By Nasdaq GlobeNewswire

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

16 Nov 2023 08:30:59 By Nasdaq GlobeNewswire

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

08 Nov 2023 16:05:51 By Nasdaq GlobeNewswire

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

02 Nov 2023 09:05:57 By Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

30 Oct 2023 16:01:20 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

17 Oct 2023 08:30:41 By Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes

05 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

28 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

31 Aug 2023 08:30:41 By Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

31 Jul 2023 16:01:28 By Nasdaq GlobeNewswire

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment

23 Jun 2023 21:54:37 By Nasdaq GlobeNewswire